Journal of the International AIDS Society最新文献

{"title":"Understanding Adolescent Anti-Retroviral Therapy Use in the BREATHER-Plus Trial: Qualitative Findings From South Africa and Uganda","authors":"Londiwe Shandu,&nbsp;Stella Namukwaya,&nbsp;Tamlyn Carmin Seunanden,&nbsp;Nothando Ngwenya,&nbsp;Moherndran Archary,&nbsp;Cissy Kityo,&nbsp;Deborah Ford,&nbsp;Sarah L. Pett,&nbsp;Adeodata R. Kekitiinwa,&nbsp;Sarah Bernays,&nbsp;Janet Seeley,&nbsp;the BREATHER-Plus trial team","doi":"10.1002/jia2.70207","DOIUrl":"10.1002/jia2.70207","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The BREATHER-Plus trial was an open-label, randomized non-inferiority trial comparing weekends off antiretroviral therapy (ART) (short cycle therapy [SCT]) with daily oral ART (continuous therapy [CT]) for adolescents aged 12–19 years. We present findings from the qualitative sub-study on the factors influencing trial participants’ decisions to take/not take ART in accordance with their randomized arm.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Qualitative data collection was conducted in South Africa and Uganda from December 2022 to July 2024 using in-depth interviews (IDIs) and focus group discussions (FGDs). We purposively recruited 29 trial participants (14 SCT/15 CT arm) to take part in IDIs in South Africa. From the trial sites in both countries, 47 trial participants, 17 non-trial participants, 15 caregivers and 16 healthcare providers took part in FGDs. Data collection with trial participants focused on adherence to SCT compared to daily ART; the acceptability of SCT and the experience of taking part in the trial. All FGDs explored the feasibility of SCT and preferences for alternative approaches to accessing therapy. Data were analysed thematically.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Both IDI and FGD data showed that the opportunity to have weekends off from treatment was welcomed by participants, caregivers and healthcare providers. However, the understanding of “2 days off” treatment was interpreted flexibly by some participants. Trial participants in both arms described their fluctuating adherence practices both prior to and during the trial. The introduction of SCT as a possibility through the trial prompted some to talk about previously concealed missed doses. Participants reported that they only mentioned missed doses in the clinic if they had a raised viral load result or had returned to the clinic with too many pills. Many participants relied on their viral load result to confirm that non-adherent behaviour was not problematic.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our findings offer insights into the factors that shape ART adherence among adolescents living with HIV. Adherence is not a static behaviour but a socially embedded and relational practice, shaped by adolescents’ interpretations of treatment, interpersonal relationships and the structure of care environments. Regimen modification alone does not resolve the broader social and emotional challenges adolescents face.</p>\u0000 </section>\u0000 </div>","PeriodicalId":201,"journal":{"name":"Journal of the International AIDS Society","volume":"29 9","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13596911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149023382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of a Peer Support Intervention for Oral Pre-Exposure Prophylaxis Uptake and Adherence Among Adolescent Girls and Young Women at Risk of HIV Acquisition in Kampala, Uganda: A Randomized Controlled Trial","authors":"Yunia Mayanja,&nbsp;Andrew Abaasa,&nbsp;Kenneth Roger Katumba,&nbsp;Matthew Spinelli,&nbsp;Bernard Kikaire,&nbsp;Monica Gandhi,&nbsp;Kyriaki Kosidou,&nbsp;Anna Mia Ekstrom,&nbsp;Eugene Ruzagira","doi":"10.1002/jia2.70210","DOIUrl":"10.1002/jia2.70210","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Introduction&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Daily oral pre-exposure prophylaxis (PrEP) use remains low among adolescent girls and young women (AGYW). We evaluated whether a peer support intervention improved daily oral PrEP uptake and adherence among AGYW at high risk of HIV acquisition in Kampala, Uganda.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We conducted an open-label randomized controlled trial (January 2023−June 2024) among 14- to 24-year-olds engaged in sex work. Eligible participants were randomized 1:1 to receive either health worker counselling only (control) or supplemented with peer support (intervention). Peer leaders delivered co-created peer education sessions starting 1 month after enrolment. Participants were followed for 12 months. Co-primary outcomes were PrEP uptake (yes/no) and adherence, evaluated using two separate measures; optimal if: ≥85% pill-counts (primary measure); positive point-of-care urine tenofovir test. Both arms received adherence counselling based on urine results. Secondary outcomes: PrEP persistence (time to discontinuation) and cost-effectiveness (cost per disability adjusted life year/DALY averted). Analysis used logistic regression (uptake); generalized estimating equations (adherence), Cox regression (persistence) and incremental cost-effectiveness ratio (ICER) below US$537 per DALY averted was considered cost-effective.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We enrolled 394 participants (197 per arm) with a mean age of 19.4 (SD ±2.3) years. The intervention did not impact PrEP uptake (OR 1.15; 95% CI 0.77−1.71) but improved adherence, pill count (OR 2.20; 95% CI 1.23−3.95) and urine assay (OR 2.18; 95% CI 1.22−3.91). Optimal adherence was low but significantly higher in the intervention by both measures: pill count (intervention = 54.8%, control = 39.6%, &lt;i&gt;p&lt;/i&gt; = 0.008), urine assay (intervention = 54.8%, control = 40.8%, &lt;i&gt;p&lt;/i&gt; = 0.001). Median duration before PrEP discontinuation was 38 days (IQR 0–319 days); intervention (56 days), control (29 days). The intervention had no effect on persistence (HR 0.86; 95% CI 0.64−1.14). It was cost-effective with the urine tenofovir assay (ICER = $459) but not with pill counts (ICER = $581).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This peer-led intervention improved PrEP adherence among AGYW in Kampala and is recommended in high-incidence settings. Urine tenofovir testing can be used to assess adherence if affordable. Enhanced peer support strategies are needed until long-acting PrEP becomes accessible and acceptable. Future research shoul","PeriodicalId":201,"journal":{"name":"Journal of the International AIDS Society","volume":"29 9","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149011752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dolutegravir Is Associated With Lower Odds of Gestational Diabetes Compared to Other Antiretroviral Therapy Regimens Among Pregnant Women in India: A Cross-Sectional Analysis","authors":"Puja Chebrolu,&nbsp;Farheen Ahmed,&nbsp;Sanjaykumar Tambe,&nbsp;Mallika Alexander,&nbsp;Priyanka Raichur,&nbsp;Aditi Kole,&nbsp;Sonali Kante,&nbsp;Vandana Kulkarni,&nbsp;Nikhil Gupte,&nbsp;Ramesh Bhosale,&nbsp;Shilpa Naik,&nbsp;Amita Gupta,&nbsp;Todd T. Brown,&nbsp;Jyoti S. Mathad","doi":"10.1002/jia2.70200","DOIUrl":"10.1002/jia2.70200","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Introduction&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In non-pregnant adults living with HIV, dolutegravir is associated with weight gain and increased type 2 diabetes risk. In pregnancy, data on the effect of dolutegravir on gestational diabetes (GDM) risk is inconclusive. Data are particularly limited in Asian populations, where diabetes risk is especially high and not always associated with weight gain. We examined the association of dolutegravir with GDM among women living with HIV in India.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We combined data from two cohorts of pregnant women living with HIV conducted at BJ Government Medical College in Pune, India—the PRACHITi study (2016−2019) and the PRAGATHi study (2023−present). Women were screened for GDM with the fasting 2-h 75 g oral glucose tolerance test and diagnosed by World Health Organization criteria. Demographics, anthropometrics, antiretroviral therapy (ART), CD4 count and HIV viral load were collected at screening. Multivariate logistic regression was used to determine the association between current dolutegravir use and GDM.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Of 254 women living with HIV, 99.2% (&lt;i&gt;n&lt;/i&gt; = 252) were on ART, of whom 66.3% (&lt;i&gt;n&lt;/i&gt; = 167) were on dolutegravir-, 22.6% (&lt;i&gt;n&lt;/i&gt; = 57) were on efavirenz- and 6.3% (&lt;i&gt;n&lt;/i&gt; = 16) were on protease inhibitor (PI)-based ART. Overall, median CD4 count was 549.5 cells/mm&lt;sup&gt;3&lt;/sup&gt; (IQR 401−753), and 82.2% (&lt;i&gt;n&lt;/i&gt; = 198) had undetectable viral load. Median body-mass index (BMI) was 21.3 kg/m&lt;sup&gt;2&lt;/sup&gt; (IQR 19.4−23.8). The prevalence of GDM was 11.8% (&lt;i&gt;N&lt;/i&gt; = 30). Among women on dolutegravir-based ART, the prevalence was 10.8% (&lt;i&gt;N&lt;/i&gt; = 18); among women on efavirenz-based ART, the prevalence was 12.3% (&lt;i&gt;N&lt;/i&gt; = 7), and the prevalence was 25% (&lt;i&gt;N&lt;/i&gt; = 4) among women on PI-based ART. Compared to women not taking dolutegravir, women taking dolutegravir had similar age and BMI but greater weight gain from the second to the third trimester (3.7 vs. 2.9 kg, &lt;i&gt;p&lt;/i&gt; &lt;0.01) and infant birthweight percentile (14.2 vs. 6.9, &lt;i&gt;p&lt;/i&gt; &lt;0.01). On multivariate logistic regression, dolutegravir use was associated with lower odds of GDM than other ART (aOR 0.2, 95% CI 0.1−1.0) irrespective of viral load and time on ART. Older age (aOR 1.1, 95% CI 1.1−1.2) and second-trimester BMI (aOR 1.2 per kg/m&lt;sup&gt;2&lt;/sup&gt;, 95% CI 1.1−1.3) were also associated with GDM.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Women on dolutegravir had lower odds of GDM compared to women taking other ART, despite greater weight gain. Ongoing","PeriodicalId":201,"journal":{"name":"Journal of the International AIDS Society","volume":"29 9","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591013/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149011755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The HIV Landscape for Transgender Women Living in Southwest Asia and North Africa: A Scoping Review","authors":"Ala Koreitem,&nbsp;Sasha Abdallah Fahme,&nbsp;Parya Saberi","doi":"10.1002/jia2.70206","DOIUrl":"https://doi.org/10.1002/jia2.70206","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>This scoping review aimed to characterize the prevalence and determinants of HIV acquisition among transgender women in Southwest Asia and North Africa (SWANA), to describe HIV preventive activities and measures, and to examine barriers to HIV and gender-affirming care, including experiences of stigma, discrimination and mental health challenges among transgender women in the region.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We searched PubMed, PsycINFO and CINAHL for any articles published through 12 June 2026, that included transgender women, used primary or secondary data and were published in Arabic or English. Studies meeting these criteria were screened in Covidence. Discrepancies were resolved following data extraction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 276 articles were identified (152 duplicates removed). After screening titles and abstracts, 49 full texts were assessed for eligibility. The articles included (<i>N</i> = 23) were primarily cross-sectional studies (<i>N</i> = 20) conducted in Iran, Lebanon, Turkey, Morocco and Tunisia. Three were non-randomized experimental studies; one intervention was designed specifically for transgender women, focusing on gender affirmation and social support. Cross-sectional studies examined HIV prevention, sexual activities and mental health. Condomless receptive anal intercourse and low HIV testing rates were most common among those engaged in sex work, which was attributed to coercion, perceived low risk for HIV acquisition or fear of disclosing one's HIV status. Stigma, physical and sexual violence, anxiety, depression and suicidality were highly prevalent among transgender women in SWANA and served as barriers to accessing healthcare services, including HIV and gender-affirming care.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>This review highlights critical areas for trans-specific interventions addressing transgender women's needs in SWANA, where HIV incidence remains on the rise.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Future longitudinal research is needed to evaluate the effectiveness of interventions in reducing HIV rates, improving mental health outcomes and mitigating structural barriers hindering healthcare access among transgender women in SWANA.</p>\u0000 </section>\u0000 </div>","PeriodicalId":201,"journal":{"name":"Journal of the International AIDS Society","volume":"29 9","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jia2.70206","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148994396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Thank You Note to Our Peer Reviewers (2025)","authors":"Kenneth H. Mayer,&nbsp;Annette H. Sohn,&nbsp;Linda-Gail Bekker,&nbsp;Marlène Bras","doi":"10.1002/jia2.70205","DOIUrl":"https://doi.org/10.1002/jia2.70205","url":null,"abstract":"&lt;p&gt;The &lt;i&gt;Journal of the International AIDS Society&lt;/i&gt; (JIAS) would like to express our gratitude to the peer reviewers who contributed to reviewing articles for the journal in 2025, and to those senior scientists who have mentored early career researchers in reviewing.&lt;/p&gt;&lt;p&gt;Your time and expertise are crucial to upholding the quality of this publication, and we are thankful for your engagement.&lt;/p&gt;&lt;p&gt;We also wish to extend our appreciation to the JIAS Editorial Board members, Deputy Editors, Statistical Committee and Ethical Committee members for their valuable contributions in assessing and reviewing submitted articles.&lt;/p&gt;&lt;p&gt;Kenneth Mayer, co-Editor-in-Chief&lt;/p&gt;&lt;p&gt;Annette Sohn, co-Editor-in-Chief&lt;/p&gt;&lt;p&gt;Linda-Gail Bekker, co-Editor-in-Chief&lt;/p&gt;&lt;p&gt;Marlène Bras, Executive Editor&lt;/p&gt;&lt;p&gt;Aaloke Mody&lt;/p&gt;&lt;p&gt;Aditya Khanna&lt;/p&gt;&lt;p&gt;Adrien Allorant&lt;/p&gt;&lt;p&gt;Ahmad Haeri Mazanderani&lt;/p&gt;&lt;p&gt;Ajay Rangaraj&lt;/p&gt;&lt;p&gt;Akarin Hiransuthikul&lt;/p&gt;&lt;p&gt;Akel Azzi&lt;/p&gt;&lt;p&gt;Akshay Sharma&lt;/p&gt;&lt;p&gt;Alison Castle&lt;/p&gt;&lt;p&gt;Alison Hill&lt;/p&gt;&lt;p&gt;Alison Rodger&lt;/p&gt;&lt;p&gt;Allan Maleche&lt;/p&gt;&lt;p&gt;Amy Justice&lt;/p&gt;&lt;p&gt;Amy Zheng&lt;/p&gt;&lt;p&gt;Anchalee Avihingsanon&lt;/p&gt;&lt;p&gt;Andrainolo Ravalihasy&lt;/p&gt;&lt;p&gt;Andreas Haas&lt;/p&gt;&lt;p&gt;Andrew David Eaton&lt;/p&gt;&lt;p&gt;Andrew Gibbs&lt;/p&gt;&lt;p&gt;Andrew Grulich&lt;/p&gt;&lt;p&gt;Andrew Mujugira&lt;/p&gt;&lt;p&gt;Angela Bengtson&lt;/p&gt;&lt;p&gt;Ann Strode&lt;/p&gt;&lt;p&gt;Antoine Jaquet&lt;/p&gt;&lt;p&gt;Ariane van der Straten&lt;/p&gt;&lt;p&gt;Arman Oganisian&lt;/p&gt;&lt;p&gt;Ashley Underwood&lt;/p&gt;&lt;p&gt;Ashwin Belludi&lt;/p&gt;&lt;p&gt;Aster Gebremedhin&lt;/p&gt;&lt;p&gt;Audrey Pettifor&lt;/p&gt;&lt;p&gt;Bao Vu&lt;/p&gt;&lt;p&gt;Beatrice Wamuti&lt;/p&gt;&lt;p&gt;Benjamin Bavinton&lt;/p&gt;&lt;p&gt;Benjamin Brown&lt;/p&gt;&lt;p&gt;Benjamin Cheabu&lt;/p&gt;&lt;p&gt;Benjamin Chi&lt;/p&gt;&lt;p&gt;Beo Oliveira Leite&lt;/p&gt;&lt;p&gt;Bindiya Meggi&lt;/p&gt;&lt;p&gt;Brenda Crabtree-Ramírez&lt;/p&gt;&lt;p&gt;Brett Millar&lt;/p&gt;&lt;p&gt;Brian Honermann&lt;/p&gt;&lt;p&gt;Brooke Nichols&lt;/p&gt;&lt;p&gt;Bruce Richman&lt;/p&gt;&lt;p&gt;Caitlin Dugdale&lt;/p&gt;&lt;p&gt;Caitlin Madevu-Matson&lt;/p&gt;&lt;p&gt;Carina Marquez&lt;/p&gt;&lt;p&gt;Carol Strong&lt;/p&gt;&lt;p&gt;Catherine Godfrey&lt;/p&gt;&lt;p&gt;Catherine Martin&lt;/p&gt;&lt;p&gt;Cedric Bien-Gund&lt;/p&gt;&lt;p&gt;Chelsea Coakley&lt;/p&gt;&lt;p&gt;Chenglin Hong&lt;/p&gt;&lt;p&gt;Chetna Jaiswal&lt;/p&gt;&lt;p&gt;Chisom Obiezu-Umeh&lt;/p&gt;&lt;p&gt;Christina Lumbantoruan&lt;/p&gt;&lt;p&gt;Christopher Akolo&lt;/p&gt;&lt;p&gt;Clara Le Saux&lt;/p&gt;&lt;p&gt;Claudia Cortes&lt;/p&gt;&lt;p&gt;Cloete Van Vuuren&lt;/p&gt;&lt;p&gt;Colette Smith&lt;/p&gt;&lt;p&gt;Colleen Kelley&lt;/p&gt;&lt;p&gt;Corwin Coppinger&lt;/p&gt;&lt;p&gt;Curtis Chan&lt;/p&gt;&lt;p&gt;Dan Tran&lt;/p&gt;&lt;p&gt;Daniel Elakpa&lt;/p&gt;&lt;p&gt;Danielle Campbell&lt;/p&gt;&lt;p&gt;Darrell Tan&lt;/p&gt;&lt;p&gt;David Denning&lt;/p&gt;&lt;p&gt;David Kietrys&lt;/p&gt;&lt;p&gt;David Van de Vijver&lt;/p&gt;&lt;p&gt;Davide Moschese&lt;/p&gt;&lt;p&gt;Deanna Kerrigan&lt;/p&gt;&lt;p&gt;Debbie Humphries&lt;/p&gt;&lt;p&gt;Deepak Mattur&lt;/p&gt;&lt;p&gt;Deja Clement&lt;/p&gt;&lt;p&gt;Denis Nash&lt;/p&gt;&lt;p&gt;Denise Franzsen&lt;/p&gt;&lt;p&gt;Denise Jacobson&lt;/p&gt;&lt;p&gt;Diane Havlir&lt;/p&gt;&lt;p&gt;Diego Cecchini&lt;/p&gt;&lt;p&gt;Dion Allen&lt;/p&gt;&lt;p&gt;Dobromir Dimitrov&lt;/p&gt;&lt;p&gt;Dorlim Moiana Uetela&lt;/p&gt;&lt;p&gt;Dumbani Kayira&lt;/p&gt;&lt;p&gt;Eiichi N Kodama&lt;/p&gt;&lt;p&gt;Elaine Abrams&lt;/p&gt;&lt;p&gt;Elana Rosenthal&lt;/p&gt;&lt;p&gt;Elfriede Agyemang&lt;/p&gt;&lt;p&gt;Elijah Kakande&lt;/p&gt;&lt;p&gt;Elise Lankiewicz&lt;/p&gt;&lt;p&gt;Elizabeth Mayfield Arnold&lt;/p&gt;&lt;p&gt;Elizabeth Montgomery&lt;/p&gt;&lt;p&gt;Ellen Brazier&lt;/p&gt;&lt;p&gt;Elske Hoornenborg&lt;/p&gt;&lt;p&gt;Elzette Rousseau&lt;/p&gt;&lt;p&gt;Emily Hyle&lt;/p&gt;&lt;p&gt;Emily Namey&lt;/p&gt;&lt;p&gt;Emma Kalk&lt;/p&gt;&lt;p&gt;Erin Wilson&lt;/p&gt;&lt;p&gt;Esau Joao&lt;/p&gt;&lt;p&gt;Fabian Raeber&lt;/p&gt;&lt;p&gt;Fernanda Fonseca&lt;/p&gt;&lt;p&gt;Fla","PeriodicalId":201,"journal":{"name":"Journal of the International AIDS Society","volume":"29 9","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jia2.70205","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148994397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Have We Met Before? Findings on HIV Retesting in Routine Healthcare Settings, Using Eswatini HIV-1 Recent Infection Surveillance Data","authors":"Claire C. Steiner,&nbsp;Eugenie A. Poirot,&nbsp;Samkelo Simelane,&nbsp;Dumile Sibandze,&nbsp;Lenhle Dube,&nbsp;Vusie Lokotfwako,&nbsp;Jessica Justman,&nbsp;Kathryn Lupoli,&nbsp;Trudy Dobbs,&nbsp;Munyaradzi Pasipamire,&nbsp;Cebisile Ngcamphalala,&nbsp;Ruben Sahabo,&nbsp;Harriet Nuwagaba-Biribonwoha,&nbsp;Suzue Saito","doi":"10.1002/jia2.70187","DOIUrl":"10.1002/jia2.70187","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Eswatini is rapidly approaching the conditions needed to achieve and sustain HIV epidemic control. Repeating diagnostic testing of people living with HIV (PLHIV) already on antiretroviral therapy (ART) is not typically indicated, can lead to misidentification of new HIV diagnoses and distorts estimates of progress towards epidemic control. This study aimed to quantify retesting among PLHIV on ART and identify associated characteristics, using biomarker-based Recent Infection Surveillance data from routine HIV testing in Eswatini.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The Eswatini HIV-1 Recent Infection Surveillance (EHRIS) programme, launched in July 2019, offered a rapid test for recent infection (RTRI) to PLHIV 15 years and older who tested HIV-positive during routine HIV testing. We analysed survey data collected from 208 HIV testing locations (facility- and community-based) between July 2019 and February 2024. The analysis included data of PLHIV who did not disclose a prior HIV diagnosis during pre-test counselling and subsequently underwent an RTRI. We defined retesting among PLHIV with RTRI recent and VL &lt;1000 copies/mL. Data were analysed to evaluate characteristics of retesting using Rao−Scott chi-square, bivariable and multivariable logistic regression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 1925 adults who provided blood specimens for RTRI and VL testing, 781 (40.6%: 95% CI, 37.1–44.1) had suppressed VLs and were classified as retesting and likely on ART. The adjusted odds ratio (aOR) of retesting was higher if testing occurred at community locations (aOR = 1.9, <i>p</i> = 0.0007), during periods of more restrictive stay-at-home policy (aOR = 1.7, <i>p</i> = 0.005, aOR 2.6, <i>p</i>&lt;0.0001, aOR = 2.1, <i>p</i>&lt;0.0001), among females (aOR = 1.6, <i>p</i> = 0.002), pregnant females (aOR = 1.8, <i>p</i> = 0.001), co-habiting (aOR = 1.8, <i>p</i> = 0.02) or self-reported prior HIV testing (aOR = 1.3, <i>p</i> = 0.03).·</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Retests for HIV account for over a third of PLHIV with RTRI recent results in Eswatini. These findings can be used to improve the accuracy of models used to estimate national epidemic trends. Possible mitigation strategies could include strengthening client-centred care, better pre-test counselling, and integrated data systems to confirm previous HIV care status and minimize unnecessary HIV testing of PLHIV who are already on ART.</p>\u0000 </section>\u0000 </div>","PeriodicalId":201,"journal":{"name":"Journal of the International AIDS Society","volume":"29 9","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13579381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148975460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing Approaches for Estimating Counterfactual HIV Incidence Among Populations With High Vulnerability to HIV in Lima, Peru: A Multi-Study Comparative Analysis","authors":"Fei Gao,&nbsp;Sayan Dasgupta,&nbsp;Siavash Pasalar,&nbsp;Qi Wang,&nbsp;Ricardo Alfaro,&nbsp;Delia Pinto-Santini,&nbsp;Thiago S. Torres,&nbsp;Jorge Sanchez,&nbsp;Javier R. Lama,&nbsp;Valdilea G. Veloso,&nbsp;Michal Juraska,&nbsp;Robinson Cabello,&nbsp;Jorge O. Alarcon,&nbsp;Beatriz Grinsztejn,&nbsp;Carlos F. Caceres,&nbsp;James F. Rooney,&nbsp;Ann Duerr","doi":"10.1002/jia2.70204","DOIUrl":"10.1002/jia2.70204","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Introduction&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The availability of highly efficacious HIV pre-exposure prophylaxis (PrEP) makes it unethical or infeasible to conduct inactive/placebo-controlled trials to evaluate new HIV prevention options. As a result, randomized active-control non-inferiority trials are typically employed; however, they require large sample sizes and extended follow-up. Moreover, their results can be hard to interpret. An alternative approach compares HIV incidence among individuals receiving a new PrEP product to a counterfactual incidence estimate—an estimate of what the HIV incidence would have been in the absence of PrEP.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We leveraged data from three studies (AMP, Sabes and ImPrEP seroincidence) conducted among men who have sex with men and transgender persons in Lima, Peru, between 2013 and 2022 to estimate the counterfactual HIV incidence for two target populations represented by a clinical trial (AMP) and a non-interventional cohort study (Sabes). We evaluated three estimation methods: prospective cohort follow-up, recency testing and rectal gonorrhoea (RG) approaches. These approaches were compared directly using data from the same study, and we further assessed population adjustment approaches by comparing estimates across studies.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;All three methods produced consistent HIV incidence estimates when applied to data collected from the same study. ​However, estimates differed when data from external studies were used, even after propensity score (PS) adjustment. For example, estimates for the AMP population using Sabes or ImPrEP data remained higher than the AMP gold-standard estimate. In contrast, adjusted estimates for the Sabes population using AMP or ImPrEP data were lower than the Sabes follow-up estimate. These differences underscore the challenges of applying external data and highlight the role of unmeasured population heterogeneity.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Counterfactual HIV incidence estimates can support evaluation of new PrEP agents when direct placebo comparisons are not possible. Estimates from recency-testing and RG approaches are promising when prospective follow-up is infeasible, but their validity depends on data quality and population similarity. PS methods improve comparability across populations but cannot fully account for unobserved differences. Triangulating across methods and sources can improve confidence in counterfactual estimates, which should be interpreted with careful attention to p","PeriodicalId":201,"journal":{"name":"Journal of the International AIDS Society","volume":"29 9","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575769/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148965776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adding a Prevention Intervention to an Established App: The Blued+ HIV Prevention Pilot Study in Beijing and Chengdu, China","authors":"Aaron J. Siegler,&nbsp;Guodong Mi,&nbsp;Fei Yu,&nbsp;Daniel Stegmueller,&nbsp;Kunru Ning,&nbsp;Shi Hao Ernest Koh,&nbsp;Yufen Liu,&nbsp;Kimberly A. Powers,&nbsp;Stefan Baral,&nbsp;Patrick S. Sullivan,&nbsp;Wenting Huang","doi":"10.1002/jia2.70203","DOIUrl":"10.1002/jia2.70203","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>HIV incidence among men who have sex with men (MSM) in China remains high, and the use of effective tools such as pre-exposure prophylaxis (PrEP) is suboptimal. Smartphone app interventions are promising yet rarely move beyond the research sphere. Rather than inventing stand-alone apps that rarely come to scale, integrating health interventions into existing multifunction apps would be a paradigm shift for research and practice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a prospective, single-arm pilot study of an intervention platform built directly into Blued, a geosocial networking (dating) app for MSM with more than 6 million users in China. The intervention provided telePrEP care (including in-app clinician services, reimbursed laboratory testing and mailed PrEP prescriptions), health messaging, and an order platform for home HIV tests and condoms. The pilot study, in Beijing and Chengdu, compared the intervention to contemporary repeated cross-sectional comparison surveys. Primary outcomes were benchmarks for feasibility (≥30% home HIV test orders and ≥20% HIV PrEP prescriptions) and acceptability (≥71 System Usability Scale [SUS] score). Preliminary efficacy assessment compared changes in the intervention group to the repeated comparison groups with generalized estimating equations (GEE) models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>From July 2022 to December 2024, 423 people started the pilot intervention, 400 (95%) were retained at 6 months and 399 (94%) at 12 months. All primary outcomes at 12 months were significantly higher than prespecified benchmarks: 87% (366/423) ordered HIV tests, 42% (176/423) received PrEP prescriptions, and the mean SUS score was 73/100. In GEE models adjusting for group characteristics and the secular trend of the comparison groups, between baseline and 12 months, the intervention group had an absolute increase in PrEP use of 20% (95% CI: 13%–27%) and in HIV testing of 7% (95% CI: 1%–13%). There was no difference in condom use.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In this study, we found that it is feasible and acceptable to incorporate HIV prevention interventions into existing apps. This model, with encouraging preliminary efficacy data, represents a new public-private model for improving uptake of evidence-based prevention interventions. Future research should test this model in a randomized clinical trial.</p>\u0000 </section>\u0000 </div>","PeriodicalId":201,"journal":{"name":"Journal of the International AIDS Society","volume":"29 9","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148965766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence, Patterns and Implications of Chemsex Substance Use Among Gay and Bisexual Men Who Have Sex With Men: A Cohort-Collaboration Between the Swiss HIV Cohort Study and the SwissPrEPared Study","authors":"Bashkim Jaha,&nbsp;Andrea Farnham,&nbsp;Roger Kouyos,&nbsp;Jan Fehr,&nbsp;Babette L. Winter,&nbsp;Irene A. Abela,&nbsp;Marcel Stöckle,&nbsp;Bernard Surial,&nbsp;Matteo Reymond,&nbsp;Matthias Cavassini,&nbsp;David Jackson-Perry,&nbsp;Luigia Elzi,&nbsp;Julia Notter,&nbsp;Benjamin Hampel,&nbsp;Katharina Kusejko","doi":"10.1002/jia2.70199","DOIUrl":"10.1002/jia2.70199","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Introduction&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Global awareness to chemsex, a specific form of sexualized psychoactive substance (“chems”) use among gay, bisexual and other men who have sex with men (gbMSM), is increasing. We aimed to assess prevalence, patterns and implications of “chems” use on chemsex-related outcomes.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We conducted a Swiss-wide longitudinal study using individual-level data from April 2019 to December 2024 of adult gbMSM with HIV, enrolled in the Swiss HIV Cohort Study (SHCS), or taking HIV pre-exposure prophylaxis (PrEP), enrolled in SwissPrEPared. Determinants of “chems” (methamphetamine, new psychoactive stimulants, GHB/GBL) use and clinical implications were analysed using logistic regression. Longitudinal “chems” use patterns were distinguished by rule-based classification. Point-prevalences of “chems” use, including COVID-19 and mpox periods, were analysed using interrupted time series analysis.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We analysed 107,855 follow-up visits from 13,304 gbMSM. “Chems” were used by 17.2% of gbMSM (21.4% in SwissPrEPared vs. 11.2% in the SHCS). Age below 26 (compared to 26−37, adjusted odds ratio [aOR]: 0.82, 95%-confidence interval: 0.68−0.96), over 37 (aOR for 38−48: 0.84, 0.75−0.94; aOR for over 48: 0.54, 0.47−0.62) and bisexual orientation showed lower odds (aOR: 0.78, 0.66−0.90), while participation in French-speaking SwissPrEPared centres (aOR compared to SHCS Eastern Switzerland: 1.41, 1.22−1.64) and sex with non-steady partners showed higher odds for “chems” use (aOR: 12.44, 8.85−18.17). “Chems” use was associated with depression, inconsistent condom use, high non-steady partner count and sexually transmitted infections (STIs). Comparing longitudinal use patterns, temporally restricted use, that is, recovering from stable use, reported “chems” use only once, or for a single episode shorter than 1 year, showed the lowest risk for STIs and high partner count, whereas intermittent use showed lower risk only for syphilis. “Chems” use decreased marginally during COVID-19 and mpox, with a quick return and no difference to levels before COVID-19.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A large proportion of gbMSM use “chems,” with congruent determinants across both cohorts but heterogeneous impact on sexual and mental health that varies by specific substance and longitudinal use patterns. Further understanding of underlying mechanisms driving this heterogeneity is needed before delivering mechanism-informed interventions tailored to “chem","PeriodicalId":201,"journal":{"name":"Journal of the International AIDS Society","volume":"29 9","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148965745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolution of ART Medication Adherence Support and Monitoring Across IeDEA Sites: Results From Three Waves of Consortium-Wide Site Assessment Surveys, 2017, 2020 and 2023","authors":"Ellen Brazier,&nbsp;Francesca Odhiambo,&nbsp;Jessie K. Edwards,&nbsp;Lauren Zalla,&nbsp;Charles Kasozi,&nbsp;Eugene Messou,&nbsp;Chantel Schreuder,&nbsp;Romanee Chaiwarith,&nbsp;María Fernanda Rodríguez,&nbsp;Irene Ayakaka,&nbsp;Marcel Zannou,&nbsp;Aimee Freeman,&nbsp;Peter Vanes Ebasone,&nbsp;Dina Muktiarti,&nbsp;Aggrey Semeere,&nbsp;Vohith Khol,&nbsp;Ephrem Mensah,&nbsp;Carina Cesar,&nbsp;Frank Tanser,&nbsp;Edwin Sang,&nbsp;Cuong Duy Do,&nbsp;Armel Poda,&nbsp;Annabelle Niyongabo,&nbsp;Yanink Caro Vega,&nbsp;Jonathan Arthur Colasanti,&nbsp;Idiovino Rafael,&nbsp;Patricia Lelo,&nbsp;Gad Murenzi,&nbsp;Denis Nash,&nbsp;the International Epidemiology Databases to Evaluate AIDS (IeDEA)","doi":"10.1002/jia2.70197","DOIUrl":"10.1002/jia2.70197","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Introduction&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Since 2013, global HIV treatment guidelines have included recommendations for medication adherence support and monitoring for people on antiretroviral therapy (ART). We examined the implementation of recommended strategies for adherence support and monitoring for adults with HIV through serial cross-sectional structured surveys conducted by the International epidemiology Databases to Evaluate AIDS (IeDEA).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We used data from surveys completed by HIV clinics across 43 countries in 2017 (&lt;i&gt;n&lt;/i&gt; = 206), 2020 (&lt;i&gt;n&lt;/i&gt; = 200) and 2023 (&lt;i&gt;n&lt;/i&gt; = 214); 131 clinics completed all three surveys. We used descriptive statistics to examine clinic resources and routine adherence support and monitoring at each time point, stratified by country income level (i.e. low/middle-income vs. high-income countries [LMICs/HICs]), and trends among clinics completing all three surveys. We created composite measures of the level or intensity of routine provision of adherence aids/reminders, adherence support and adherence monitoring, ranging from “none” to “enhanced” levels. Among clinics participating in the 2023 survey, we also examined adherence aids and support routinely provided to clients eligible for intensified support versus all clients.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;At each time point, surveyed clinics were predominantly in LMICs (68.4%−74.3%) and urban settings (65.0%−65.5%), situated within health centres (60.2%−64.0%) or regional/provincial or university hospitals (28.0%−33.5%). Among 131 clinics participating in all surveys, there was a decrease in the provision of multiple adherence readiness counselling sessions from 52.2% of clinics reporting ≥2 sessions before treatment initiation in 2017 to 26.0% in 2023, along with increased provision of 6-month ART refills (from 11.5% to 40.5%). The provision of “enhanced” levels of adherence support to all clients decreased from 2017 to 2023 in both LMICs (64.6% to 28.1%) and HICs (34.3% to 8.6%); in 2023, substantial proportions of clinics reported that such support was routinely provided only to clients eligible for intensive adherence support. At each time point, higher proportions of clinics in LMICs reported “enhanced” adherence monitoring than in HICs (63.5%−70.8% vs. 31.4%−54.3%).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;While streamlined provision of ART adherence support may reflect the implementation of guidelines recommending the targeting of support towards clients with known or suspected adher","PeriodicalId":201,"journal":{"name":"Journal of the International AIDS Society","volume":"29 9","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13542704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148885895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}